Research shows weight loss surgery can help reduce the risk of severe liver problems for some patients with MASH.

The tool reduces pathologist variability in liver biopsy assessment during trials of treatments for metabolic ...

† NASHTest is a combination of age, gender, height, weight serum triglycerides, cholesterol, α2-macroglobulin, apolipoprotein A1, haptoglobin, γ ...

Fatty liver disease occurs when more than 5-10% of the liver's weight is made up of fat. This can lead to inflammation in the ...

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...

Galectin Therapeutics (NASDAQ:GALT – Get Free Report) is expected to issue its quarterly earnings data before the market ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) and Biomea Fusion (NASDAQ:BMEA – Get Free Report) are both small-cap ...

Resmetirom is a medication approved by the FDA to treat adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...